302
Participants
Start Date
September 14, 2023
Primary Completion Date
September 14, 2028
Study Completion Date
September 14, 2028
Fludarabine
30 mg/m2/day IV fludarabine for 5 days (day-6 to day-2)
Busulfan
130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
ATG
Thymoglobuline®: 2.5 mg/Kg/day IV for 2 consecutive days (day -2 and -1)
Clofarabine
30 mg/m2/day IV clofarabine for 5 days (day-6 to day-2)
RECRUITING
CHU de Nantes, Nantes
NOT_YET_RECRUITING
CHU Amiens, Amiens
RECRUITING
CHU Angers, Angers
NOT_YET_RECRUITING
CHU Besançon, Besançon
NOT_YET_RECRUITING
CHU Bordeaux, Bordeaux
RECRUITING
CHU Brest, Brest
RECRUITING
CRLC Caen, Caen
NOT_YET_RECRUITING
CHU Clermont-Ferrand, Clermont-Ferrand
NOT_YET_RECRUITING
APHP Créteil, Créteil
RECRUITING
CHU Grenoble, Grenoble
NOT_YET_RECRUITING
CHRU Lille, Lille
NOT_YET_RECRUITING
CHU Limoges, Limoges
NOT_YET_RECRUITING
CHU Lyon, Lyon
NOT_YET_RECRUITING
Institut Paoli Calmettes, Marseille
RECRUITING
CHU Montpellier, Montpellier
NOT_YET_RECRUITING
CHRU Nancy, Nancy
NOT_YET_RECRUITING
CHU Paris St-Louis, Paris
NOT_YET_RECRUITING
Pitie-Salpetriere, APHP, Paris
NOT_YET_RECRUITING
St-Antoine, APHP, Paris
NOT_YET_RECRUITING
CHU Poitiers, Poitiers
NOT_YET_RECRUITING
CHU Rennes, Rennes
NOT_YET_RECRUITING
CHU St-Etienne, Saint-Etienne
RECRUITING
CRLC Toulouse, Toulouse
Nantes University Hospital
OTHER